Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Berkshire Hathaway Inc Class B (BRK.B) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Berkshire Hathaway Inc Class BTrade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Berkshire Hathaway Inc Class B vs Citius Pharmaceuticals Inc — how do they compare? Berkshire Hathaway Inc Class B trades at $509.06, while Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M). The key difference: Berkshire Hathaway Inc Class B is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

BRK.BCTXR
Sector
FinancialsHealth
52-Week High
$529.65$1.82
52-Week Low
$465.39$0.48
Market Cap
$20.01M
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Berkshire Hathaway Inc Class B

BRK.B trades at $510.23, down 3.67% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. Analyst consensus is positive with 57% buy ratings. The stock's fundamentals reflect Berkshire Hathaway's diversified holdings and strong cash flow, though specific valuation ratios are not provided in the snapshot.

The outlook remains favorable due to strong analyst support and technical momentum, but risks include market volatility and economic uncertainties. Investment opportunity lies in the company's robust business model, while caution is advised near current resistance levels.

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Berkshire Hathaway Inc Class B

Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.

Read more on BRK.B

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR